Millipore

Syncell Appoints Life Science Industry Leaders Dr. Martin Madaus and Dr. Don Kania as Business Strategic Advisors

Retrieved on: 
Thursday, October 19, 2023
Health, Health Technology, Other Science, General Health, Science, Biotechnology, The Carlyle Group, Intuitive Surgical, Protein, Growth, Ortho Clinical Diagnostics, Therapy, Proteomics, FEI Company, Medical device, Management, Millipore

Syncell, a life science technology company developing tools for next-generation proteome research, proudly announces the appointment of Dr. Martin Madaus and Dr. Don Kania as the new Business Strategic Advisors of the company.

Key Points: 
  • Syncell, a life science technology company developing tools for next-generation proteome research, proudly announces the appointment of Dr. Martin Madaus and Dr. Don Kania as the new Business Strategic Advisors of the company.
  • With their extensive backgrounds in the life science industry, both Dr. Madaus and Dr. Kania will guide Syncell's growth and innovation, helping the company become a major player in the spatial proteomics industry.
  • Dr. Madaus shared enthusiasm about his new role: “Syncell is pushing the boundaries of spatial proteomics with its innovative Microscoop technology.
  • As strategic business advisors, Dr. Madaus and Dr. Kania will provide guidance and collaborate with Syncell on various aspects of its operations, including business strategy, commercialization planning, product development, and fundraising efforts.

Avantor® Announces Ger Brophy to Retire in 2024; Benoit Gourdier Appointed EVP, Biopharma Production

Retrieved on: 
Tuesday, September 26, 2023
Avantor, AVTR, Senior, EVP, Merck Group, Retirement, Millipore, Growth, NYSE, Sigma-Aldrich, Management

Mr. Gourdier will succeed Dr. Ger Brophy, who will retire from the company on February 29, 2024.

Key Points: 
  • Mr. Gourdier will succeed Dr. Ger Brophy, who will retire from the company on February 29, 2024.
  • Following his retirement, Dr. Brophy will continue to serve as an advisor to the company as well as Chair of the Avantor Scientific Advisory Board.
  • Mr. Gourdier joins Avantor with more than 25 years in the life sciences industry, with a track record of driving growth and leading global commercial organizations.
  • Added Stubblefield, "Ger has been instrumental to building our bioproduction capabilities, scaling our global manufacturing and R&D, and deepening customer relationships.

Bruno Rossi joins Olink as Chief Commercial Officer

Retrieved on: 
Tuesday, March 21, 2023
Leica Microsystems, Organic chemistry, Marketing, Danaher, Merck Group, CCO, Proteomics, Sales operations, Bruno, Growth, Merck, Management, Millipore

UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately.

Key Points: 
  • UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately.
  • Mr. Rossi will lead the Company’s global commercial organization including Sales, Marketing and Sales Operations.
  • “I am delighted to welcome Bruno to the Olink organization, and look forward to the value his considerable industry experience will add to our rapidly growing company.” said Carl Raimond, President of Olink.
  • “With its best-in-class technology, leading commercial organization, and tremendous talent, Olink has positioned itself as a major force within the next-generation proteomics market,” said Bruno Rossi, CCO of Olink.

Berkshire Sterile Manufacturing opens sterility isolator for onsite sterility testing

Retrieved on: 
Tuesday, June 28, 2022
Patient, Lee, Massachusetts, BSM, GLOBE, Laboratory, Microbiology, GMP, Quality control, FCTS, CMO, Hydrogen peroxide, Human, Medicine, Medical device, Millipore

Lee, MA, June 28, 2022 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a fill finish CMO located in Lee, MA, is proud to announce their sterility testing isolator is ready to perform onsite sterility testing for its GMP batches.

Key Points: 
  • Lee, MA, June 28, 2022 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a fill finish CMO located in Lee, MA, is proud to announce their sterility testing isolator is ready to perform onsite sterility testing for its GMP batches.
  • Sterility testing confirms the filled drug product is free of microbes that could cause patients to become sick administered with the medicine.
  • The isolator and sterility tester are now available to begin onsite sterility testing for drug product lots produced at BSM.
  • BSM has already scheduled testing, and the company is celebrating the opening of its new sterility isolator line with an informal ribbon cutting ceremony in early July.

Erbi Biosystems Strengthens Executive Leadership Team with Appointment of Chief Scientific Officer

Retrieved on: 
Tuesday, May 31, 2022
ISCT, B cell, Knowledge, International Society, Blood, Research, Urine, GMP, Millipore, PH, Brad Hamilton, KLA, University, RNA interference, Society, CHO, Glossary, Gene, Stemgent, Industry, James Madison University, MS, RNA, Technology, ISSCR, Skin, Hazel Erby, CO2, International Society for Stem Cell Research, Cell, Growth, CEO, Management, Vaccine, Fine chemical, Biology, Biotechnology

BOSTON, May 31, 2022 /PRNewswire/ -- Erbi Biosystems, Inc., a global leader in dose-scale, fully automated microbioreactors for cell therapy development and manufacturing, today announced the appointment of Brad Hamilton to the position of Chief Scientific Officer, effective immediately.

Key Points: 
  • BOSTON, May 31, 2022 /PRNewswire/ -- Erbi Biosystems, Inc., a global leader in dose-scale, fully automated microbioreactors for cell therapy development and manufacturing, today announced the appointment of Brad Hamilton to the position of Chief Scientific Officer, effective immediately.
  • He was previously Chief Scientific Officer at GoodCell and Chief Technology Officer at ReproCELL.
  • "Brad is an exceptional scientific leader in the industry, and I am excited to have him join Erbi's executive team.
  • Mr. Hamilton's scientific leadership in the industry spans more than 25 years, including his roles as the founder and Chief Scientific Officer at GoodCell and Chief Technology Officer for ReproCELL, a multinational stem cell company focused on developing novel stem cell technologies and therapies.

Curiox Biosystems Establishes Chief Commercial Officer

Retrieved on: 
Wednesday, May 4, 2022
University, Automation, Senior, Kaufmann, Miniaturization, University of California, San Diego, Cornell University, Mechanical, Millipore, CCO, Marketing, MBA, Research, Transformation/transcription domain-associated protein, Invitrogen, Awareness, Growth, Management, Science, Illumina

WOBURN, Mass., May 4, 2022 /PRNewswire/ -- Curiox Biosystems, Inc., a global leader in biological sample preparation for life science research, today announced that it has named Don O'Neil to the newly created position of Chief Commercialization Officer (CCO).

Key Points: 
  • WOBURN, Mass., May 4, 2022 /PRNewswire/ -- Curiox Biosystems, Inc., a global leader in biological sample preparation for life science research, today announced that it has named Don O'Neil to the newly created position of Chief Commercialization Officer (CCO).
  • In 2012, Don moved to Orflo as a Senior Vice President of Sales and Strategic Partnerships and then to Gemini Biosystems as Chief Commercial Officer in 2013.
  • "We are thrilled to have Don join the Curiox team," said Curiox founder and Chief Executive Officer Dr. Namyong Kim.
  • "His passion for innovation and deep experience commercializing advanced life science technologies will be invaluable as Curiox continues its rapid growth."

BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

Retrieved on: 
Thursday, March 17, 2022
Millipore, Concern, Technology, Myocarditis, SARS, Vaccine, World Health Organization's response to the COVID-19 pandemic, Antibody, Ohio State University, ACE2, OTCQB, Cancer, Degenerative disease, RNA transfection, Journal, Our World in Data, Observation, Clinical trial, CDMO, Company, CSE, Severe acute respiratory syndrome coronavirus 2, Deutsch, Virus, Journal of Virology, Merck, Angiotensin-converting enzyme 2, Mouse, Coronavirus, FRA, Pharmaceutical industry, Omicron, BC, Delta, COVID-19, Virology

BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").

Key Points: 
  • BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").
  • The collaboration between BioVaxys and Ohio State, which has been underway since early January 2022, is evaluating the combination of BVX-0320 and BVX-1021 in a guinea pig model.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.

BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University

Retrieved on: 
Thursday, March 17, 2022
Millipore, Concern, Technology, Myocarditis, SARS, Vaccine, World Health Organization's response to the COVID-19 pandemic, Antibody, Ohio State University, ACE2, OTCQB, Cancer, Degenerative disease, RNA transfection, Journal, Our World in Data, Observation, Clinical trial, CDMO, Company, CSE, Severe acute respiratory syndrome coronavirus 2, Deutsch, Virus, Journal of Virology, Merck, Angiotensin-converting enzyme 2, Mouse, Coronavirus, FRA, Pharmaceutical industry, Omicron, BC, Delta, COVID-19, Virology

BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").

Key Points: 
  • BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University ("Ohio State") and BioVaxys, announced in December 2021, that is evaluating the Company's novel approach for a "universal vaccine" that can treat a broad range of sarbecoviruses ("pan-sarbecovirus vaccine").
  • The collaboration between BioVaxys and Ohio State, which has been underway since early January 2022, is evaluating the combination of BVX-0320 and BVX-1021 in a guinea pig model.
  • For greater certainty, BioVaxys is not making any express or implied claims that the Company can currently treat COVID-19.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Analytic, Conditional sentence, Process, SEC, Diabetes, Security (finance), NASDAQ, University, Fibrosis, Therapy, Chemical engineering, Clinical trial, Flagship Pioneering, CMC, U.S. Securities and Exchange Commission, External, Acquisition, Millipore, Protein, Membrane, University of California, Berkeley, University of Wisconsin–Madison, IND, Biotechnology, Change request, FDA, Berkeley, Agenus, Bioverativ, Enzyme, Patient, Technology, Bluebird bio, CEO, Doctor of Philosophy, Massachusetts Institute of Technology, Risk management, Medical device, Sanofi

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022.
  • We are delighted to welcome Sarah, a biopharma veteran, to the Sigilon team, said Rogerio Vivaldi, M.D., President and CEO of Sigilon.
  • Prior to joining Sigilon Therapeutics, Dr. Yuan served as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio.
  • Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform.

Arbor Biotechnologies Appoints Steven J. Favaloro as Chief Financial Officer

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, RNA transfection, Information, Growth, Carroll School of Management, CFO, Industry, Company, CDMO, Disease, Acquisition, MS, Millipore, Liver, MBA, Enzyme, Patient, Economics, Treasury, HR, CEO, Vertex Pharmaceuticals, CNS, Gene editing, Management, Pharmaceutical industry, Boston College

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Steven J. Favaloro as Chief Financial Officer.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Steven J. Favaloro as Chief Financial Officer.
  • Mr. Favaloro joins Arbor with more than a decade of financial leadership in the biopharmaceutical and life sciences space.
  • We are pleased to welcome Steve to Arbors executive team, said Devyn Smith, Ph.D., CEO, Arbor Biotechnologies.
  • Steve brings a deep understanding of capital markets and the life sciences industry and has a proven track record of successful financial leadership.